PL2214693T3 - Zastosowanie melanokortyn do leczenia insulinowrażliwości - Google Patents

Zastosowanie melanokortyn do leczenia insulinowrażliwości

Info

Publication number
PL2214693T3
PL2214693T3 PL08846334T PL08846334T PL2214693T3 PL 2214693 T3 PL2214693 T3 PL 2214693T3 PL 08846334 T PL08846334 T PL 08846334T PL 08846334 T PL08846334 T PL 08846334T PL 2214693 T3 PL2214693 T3 PL 2214693T3
Authority
PL
Poland
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
PL08846334T
Other languages
English (en)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas, Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College filed Critical Ipsen Pharma Sas
Publication of PL2214693T3 publication Critical patent/PL2214693T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL08846334T 2007-11-05 2008-11-05 Zastosowanie melanokortyn do leczenia insulinowrażliwości PL2214693T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05
PCT/US2008/012490 WO2009061411A2 (en) 2007-11-05 2008-11-05 Use melanocortins to treat insulin sensitivity
EP08846334.4A EP2214693B1 (en) 2007-11-05 2008-11-05 Use of melanocortins to treat insulin sensitivity

Publications (1)

Publication Number Publication Date
PL2214693T3 true PL2214693T3 (pl) 2016-03-31

Family

ID=40626385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08846334T PL2214693T3 (pl) 2007-11-05 2008-11-05 Zastosowanie melanokortyn do leczenia insulinowrażliwości

Country Status (20)

Country Link
US (6) US9155777B2 (pl)
EP (2) EP2979703B1 (pl)
JP (3) JP2011502987A (pl)
KR (3) KR20150013339A (pl)
CN (2) CN101980717A (pl)
AR (1) AR069461A1 (pl)
AU (1) AU2008325194B2 (pl)
BR (1) BRPI0819188B1 (pl)
CA (2) CA2952095C (pl)
DK (1) DK2214693T3 (pl)
ES (2) ES2690556T3 (pl)
HU (1) HUE026842T2 (pl)
IL (2) IL205554A (pl)
NZ (1) NZ585131A (pl)
PL (1) PL2214693T3 (pl)
PT (2) PT2214693E (pl)
RU (1) RU2453328C2 (pl)
TR (1) TR201815292T4 (pl)
TW (1) TWI374030B (pl)
WO (1) WO2009061411A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
BRPI0819188B1 (pt) 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
US20120135923A1 (en) * 2009-08-05 2012-05-31 Ipsen Pharma, S.A.S. Use of Melanocortins to Treat Dyslipidemia
CN102574894A (zh) * 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
EP2970388B1 (en) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
WO2019236679A1 (en) 2018-06-05 2019-12-12 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
WO2024108198A2 (en) * 2022-11-18 2024-05-23 Rhythm Pharmaceuticals, Inc. Methods of treating obesity with an mc4r agonist
WO2025151135A1 (en) * 2024-01-08 2025-07-17 Endevica Bio, Inc. Methods of treating cancer and/or chemotherapy related conditions using non-naturally occurring melanocortin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
EP1322954A4 (en) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst PROCESS FOR TREATING INSULIN RESISTANCE IN OBESITY AND DIABETES
PT1551834E (pt) * 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
ES2286345T3 (es) * 2003-03-20 2007-12-01 Santhera Pharmaceuticals (Schweiz) Ag Derivados de piperidina y piperazina substituidos como moduladores del receptor de melanocortina-4.
CN1764458A (zh) 2003-03-26 2006-04-26 麦克公司 作为黑皮质素－4受体激动剂的双环哌啶衍生物
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
BRPI0409976A (pt) 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
US20080200376A1 (en) * 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
BRPI0819188B1 (pt) * 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
US20120135923A1 (en) 2009-08-05 2012-05-31 Ipsen Pharma, S.A.S. Use of Melanocortins to Treat Dyslipidemia

Also Published As

Publication number Publication date
US20220339239A1 (en) 2022-10-27
IL249998A0 (en) 2017-03-30
HK1221147A1 (en) 2017-05-26
RU2453328C2 (ru) 2012-06-20
AU2008325194A1 (en) 2009-05-14
TW200932258A (en) 2009-08-01
US20150366934A1 (en) 2015-12-24
PT2979703T (pt) 2018-10-31
JP2015131827A (ja) 2015-07-23
CN103316345A (zh) 2013-09-25
CA2704651C (en) 2017-03-07
BRPI0819188B1 (pt) 2021-06-22
NZ585131A (en) 2012-10-26
HK1146242A1 (en) 2011-05-27
KR20150013339A (ko) 2015-02-04
PT2214693E (pt) 2015-12-07
WO2009061411A3 (en) 2010-04-15
AU2008325194B2 (en) 2012-04-19
ES2690556T3 (es) 2018-11-21
CA2704651A1 (en) 2009-05-14
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
CA2952095C (en) 2020-02-18
ES2555522T3 (es) 2016-01-04
IL205554A (en) 2017-01-31
BRPI0819188A2 (pt) 2015-09-01
AR069461A1 (es) 2010-01-27
KR101290623B1 (ko) 2013-08-07
TWI374030B (en) 2012-10-11
WO2009061411A2 (en) 2009-05-14
JP5964767B2 (ja) 2016-08-03
US9827286B2 (en) 2017-11-28
CN103316345B (zh) 2016-05-18
EP2214693A2 (en) 2010-08-11
US20160354429A1 (en) 2016-12-08
US20190111105A1 (en) 2019-04-18
EP2979703B1 (en) 2018-07-18
HK1184692A1 (zh) 2014-01-30
JP2011502987A (ja) 2011-01-27
US9155777B2 (en) 2015-10-13
IL205554A0 (en) 2010-12-30
RU2010122897A (ru) 2011-12-20
CN101980717A (zh) 2011-02-23
US20180303899A1 (en) 2018-10-25
EP2979703A1 (en) 2016-02-03
IL249998B (en) 2018-07-31
JP2013144690A (ja) 2013-07-25
US9439943B2 (en) 2016-09-13
KR20130065725A (ko) 2013-06-19
HUE026842T2 (en) 2016-08-29
US20100311647A1 (en) 2010-12-09
EP2214693B1 (en) 2015-09-09
EP2214693A4 (en) 2012-04-11
CA2952095A1 (en) 2009-05-14
DK2214693T3 (en) 2015-11-30
TR201815292T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
PT2214693E (pt) Utilização de melanocortinas para tratar a sensibilidade à insulina
ZA201104467B (en) Heterocyclic compounds and methods of use
ZA201104463B (en) Compounds and methods of use
IL208354A0 (en) Methods of treatment
IL207292A0 (en) Use of ranolazine for treating pain
NO2016023I1 (no) Glycerol fenylbutyrat
EP2480081A4 (en) Bridged heterocyclic compounds and methods for their use
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
GB0707750D0 (en) Treatment of organic matter
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
IL217966A0 (en) Hsl inhibitors useful in the treatment of diabetes
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
GB2448592B (en) Improvements to coffins
ZA201005783B (en) Hard to reach fracture applicator strap
GB0723100D0 (en) Treatment of HFnEF
ZA201100163B (en) Unit dosage of apadenoson
GB0814296D0 (en) Improvements to coffins
EP2066171A4 (en) ADMINISTERING A TREATMENT SUBSTANCE TO POROUS ELEMENTS
PL2346485T3 (pl) Stosowanie betainy
GB0802903D0 (en) Treatment of diabetes
GB0801958D0 (en) Improvements relating to electro-optical sensors and their use
IL190834A0 (en) Improvements to bandages
GB0816217D0 (en) Treatment of hepatitis C